Biology:Cambiogenplasmid
From HandWiki
Short description: Gene therapy medication
| Gene therapy | |
|---|---|
| Target gene | VEGF |
| Vector | Plasmid |
| Clinical data | |
| Trade names | Neovasculgen |
| Other names | Pl-VEGF165 |
| Routes of administration | Intraneural injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).[1][2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[3][4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.
References
- ↑ "Vascular endothelial growth factor gene therapy - HSCI". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800041695.
- ↑ "Gene Therapy for PAD Approved". Drug Discovery and Development. 6 December 2011. http://www.dddmag.com/news/2011/12/gene-therapy-pad-approved.
- ↑ "Neovasculogen listing in Eurolab". Eurolab. http://www.eurolab.ua/medicine/drugs/5411/.
- ↑ "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics 20 (5): 473–82. September 2015. doi:10.1177/1074248415574336. PMID 25770117.
See also
- Therapeutic angiogenesis
 |  |
